In an unexpected move, an administrative law judge dismissed a complaint in which the Federal Trade Commission alleged Impax Laboratories struck an anti-competitive deal not to market a generic version of an Endo Pharmaceuticals painkiller for three years in exchange for $112 million.

The agency had alleged that, in June 2010, Impax illegally agreed to refrain from marketing a generic version of Opana ER, an extended-release opioid. At the time the deal was reached, Opana ER generated $172 million in sales, or about 12 percent of total Endo revenues, according to the complaint filed by the FTC early last year. By then, the FTC and Endo agreed to settle charges of anti-competitive behavior.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy